ACXP Acurx Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1736243 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY11.7%
TTM EPS YoY76.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-147.5%
ROA-98.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets29.0%
Debt / equity0.00x
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-15.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $1.83M | $5.40M | $6.04M | $4.75M | $2.03M |
| SG&A expense | $6.26M | $8.72M | $8.53M | $7.34M | $10.78M |
| Operating income | -$8.09M | -$14.12M | — | — | — |
| Income tax | — | — | — | $0 | — |
| Net income | -$7.97M | -$14.10M | -$14.58M | -$12.09M | -$12.75M |
| EPS (basic) | -5.32 | -17.45 | -1.15 | -1.12 | -1.49 |
| EPS (diluted) | -5.32 | -17.45 | -1.15 | -1.12 | -1.49 |
| Weighted avg. shares (diluted) | 1.50M | 808,168 | 12.67M | 10.82M | 8.54M |
| Balance sheet | |||||
| Cash & equivalents | $7.56M | $3.71M | $7.47M | $9.11M | $12.96M |
| Current assets | — | $3.86M | $7.71M | $9.38M | $13.25M |
| Total assets | $7.69M | $3.86M | $7.71M | $9.38M | $13.25M |
| Current liabilities | $2.42M | $3.24M | $3.04M | $2.06M | $843,909 |
| Total liabilities | $2.42M | $3.24M | $3.04M | $2.06M | $843,909 |
| Shareholders' equity | $5.27M | $615,121 | $4.67M | $7.32M | $12.41M |
| Shares outstanding | 2.35M | 851,534 | 14.47M | 11.63M | 10.22M |
| Cash flow statement | |||||
| Operating cash flow | -$6.79M | -$10.38M | -$9.80M | -$7.54M | -$5.01M |
| Financing cash flow | $10.64M | $6.62M | $8.16M | $3.70M | $14.80M |
| Stock-based compensation | $1.25M | $2.60M | $3.21M | $2.87M | $5.15M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.